188 related articles for article (PubMed ID: 1378280)
21. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
Kuraya M; Yefenof E; Klein G; Klein E
Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
[TBL] [Abstract][Full Text] [Related]
22. [Complement regulatory proteins].
Miyagawa S
Nihon Rinsho; 2005 Apr; 63 Suppl 4():274-8. PubMed ID: 15861668
[No Abstract] [Full Text] [Related]
23. Measles virus and C3 binding sites are distinct on membrane cofactor protein (CD46).
Manchester M; Valsamakis A; Kaufman R; Liszewski MK; Alvarez J; Atkinson JP; Lublin DM; Oldstone MB
Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2303-7. PubMed ID: 7534417
[TBL] [Abstract][Full Text] [Related]
24. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.
Koski CL; Estep AE; Sawant-Mane S; Shin ML; Highbarger L; Hansch GM
J Neurochem; 1996 Jan; 66(1):303-12. PubMed ID: 8522968
[TBL] [Abstract][Full Text] [Related]
25. Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression.
Spiller OB; Moretto G; Kim SU; Morgan BP; Devine DV
J Neuroimmunol; 1996 Dec; 71(1-2):97-106. PubMed ID: 8982108
[TBL] [Abstract][Full Text] [Related]
26. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins.
Weis JJ; Toothaker LE; Smith JA; Weis JH; Fearon DT
J Exp Med; 1988 Mar; 167(3):1047-66. PubMed ID: 2832506
[TBL] [Abstract][Full Text] [Related]
27. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
Marquart HV; Svehag SE; Leslie RG
J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
[TBL] [Abstract][Full Text] [Related]
28. Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.
Kalli KR; Hsu PH; Bartow TJ; Ahearn JM; Matsumoto AK; Klickstein LB; Fearon DT
J Exp Med; 1991 Dec; 174(6):1451-60. PubMed ID: 1836011
[TBL] [Abstract][Full Text] [Related]
29. Short consensus repeat domain 1 of decay-accelerating factor is required for enterovirus 70 binding.
Karnauchow TM; Dawe S; Lublin DM; Dimock K
J Virol; 1998 Nov; 72(11):9380-3. PubMed ID: 9765493
[TBL] [Abstract][Full Text] [Related]
30. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
[TBL] [Abstract][Full Text] [Related]
31. Chimeric CD46/DAF molecules reveal a cryptic functional role for SCR1 of DAF in regulating complement activation.
Christiansen D; Loveland B; Kyriakou P; Lanteri M; Rubinstein E; Gerlier D
Mol Immunol; 2000; 37(12-13):687-96. PubMed ID: 11275254
[TBL] [Abstract][Full Text] [Related]
32. The effects of complement activation on platelets.
Devine DV
Curr Top Microbiol Immunol; 1992; 178():101-13. PubMed ID: 1330445
[No Abstract] [Full Text] [Related]
33. Three-dimensional structure and flexibility of proteins of the RCA family - a progress report.
Herbert A; O'leary J; Krych-Goldberg M; Atkinson JP; Barlow PN
Biochem Soc Trans; 2002 Nov; 30(Pt 6):990-6. PubMed ID: 12440959
[TBL] [Abstract][Full Text] [Related]
34. [Complement regulatory factors and immunologic recognition mechanism between species].
Seya T; Matsunoto M
Nihon Rinsho Meneki Gakkai Kaishi; 1995 Dec; 18(6):637-42. PubMed ID: 8963770
[No Abstract] [Full Text] [Related]
35. Cytokines affect resistance of human renal tumour cells to complement-mediated injury.
Blok VT; Gelderman KA; Tijsma OH; Daha MR; Gorter A
Scand J Immunol; 2003 Jun; 57(6):591-9. PubMed ID: 12791098
[TBL] [Abstract][Full Text] [Related]
36. Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo.
Christiansen D; Devaux P; Réveil B; Evlashev A; Horvat B; Lamy J; Rabourdin-Combe C; Cohen JH; Gerlier D
J Virol; 2000 May; 74(10):4672-8. PubMed ID: 10775604
[TBL] [Abstract][Full Text] [Related]
37. Organization of the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and C4-binding protein in the RCA locus on human chromosome 1.
Carroll MC; Alicot EM; Katzman PJ; Klickstein LB; Smith JA; Fearon DT
J Exp Med; 1988 Apr; 167(4):1271-80. PubMed ID: 2451706
[TBL] [Abstract][Full Text] [Related]
38. Combining MAP-1:CD35 or MAP-1:CD55 fusion proteins with pattern-recognition molecules as novel targeted modulators of the complement cascade.
Pérez-Alós L; Bayarri-Olmos R; Skjoedt MO; Garred P
FASEB J; 2019 Nov; 33(11):12723-12734. PubMed ID: 31469600
[TBL] [Abstract][Full Text] [Related]
39. Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex.
Tuveson DA; Ahearn JM; Matsumoto AK; Fearon DT
J Exp Med; 1991 May; 173(5):1083-9. PubMed ID: 1708808
[TBL] [Abstract][Full Text] [Related]
40. Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP.
Huang J; Gou D; Zhen C; Jiang D; Mao X; Li W; Chen S; Cai C
FEMS Immunol Med Microbiol; 2001 Oct; 31(3):203-9. PubMed ID: 11720816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
